PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK
Webster, S., Hau, N., Ustyugova, A.V., Kansal, A.R., Reifsnider, O.Volume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.776
Date:
October, 2018
File:
PDF, 378 KB
english, 2018